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Activin inhibition	downstream	of	receptor	engagement
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Figure 4. W-20-17 cells were serum-restricted for twenty-four hours then treated with 10 uM SB431542 for four hours.
Western blots were then performed for BMP pathway activation level (A, phosphorylated SMAD1/5/8 compared to total
SMAD1) or Activin pathway activation (B, phosphorylated SMAD2/3 compared to total SMAD2). These results indicate that
SB431542 treatment does not alleviate Activin-mediated repression of BMP signaling. * indicates p<0.05; n=3 per group.
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Working	Interpretations
ACVR2A/B modulates signals for the TGF-beta superfamily of ligands, including BMP and Activin. Activin has been shown
to counteract BMPs that signal through the ACVR2A/B receptors, however, Activin has not been shown to counteract
BMPs that signal through BMPR2.
Noggin is a BMP-specific antagonist protein, which upon addition to the W-20-17 cells resulted in a decrease in
phosphorylation of SMAD 1/5/8 and no effect on the phosphorylation of SMAD 2/3. Here we observed that BMP
inhibition upstream of the receptor does not impact SMAD 2/3 phosphorylation. Such also supports the signaling
competency of W-20-17 cells at the basal level, as seen in the control group.
Follistatin (FST) is an Activin binding protein, which upon addition to the W-20-17 cells resulted in an increase in the
phosphorylation of SMAD 1/5/8. Here we observed that Activin inhibition upstream of the receptor allows for the
upregulation of BMP signaling. SB-431542 is an intracellular inhibitor of Activin signaling, which upon addition to the W-
20-17 cells resulted in a loss of SMAD 2/3 phosphorylation.
Collectively, our data suggest that Activin mediated repression of BMP signaling is ligand dependent but occurs upstream
of effector activation.
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Figure 5. A: Optimization of lentiviral transduction method for W-20-17 cells. Fluorescent micrographs from W-20-
17 cells transduced with GFP lentivirus (right) compared to non-transduced control (Ctrl). B: W-20-17 cells were
treated with a lentivirus carrying cDNA encoding C-terminal V5-tagged human ACVR2A (ACVR2A-V5) or GFP (as a
negative control). Cells were selected using puromycin and overexpression confirmed by western blot analysis.
Western blots (V5, left; ACVR2A, right) are shown confirming expression of a V5-tagged gene for hACVR2A in
transduced W-20-17 cells compared to the beta-actin control.
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Current	Work	2:	Inhibition	of	specific	Activin ligands
Neutralizing	
Antibody
Figure	6	(left):	RT-PCR	analysis	of	Activin subunit	expression	in	W-20-17	cells	after	twenty-
four	hours	of	serum	restriction.	The	presence	of	Inhba and	Inhbb provide	the	possibility	
that	W-20-17	cells	synthesize	Activin A	and	B.	Negative	controls	”-RT”	and	“NTC”	lack	
reverse	transcriptase	and	template,	respectively.	
Figure 7. W-20-17 cells will be serum-restricted for twenty-four hours and then treated with neutralizing
antibodies against Activin A and Activin B for four hours. The cells will be lysed and western blot analyses
performed to examine the potential effect on BMP pathway activation, and results will be compared against
treatment with Follistatin. We hypothesize that, similar to Follistatin, treatment of W-20-17 cells with anti-Activin
ligand antibodies will alleviate Activin-mediated repression of BMP signaling and we will see an increase in the
phosphorylation of SMAD1/5/8.
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Current	Work	3:	Follistatin treatment	in	cells	overexpressing	ACVR2A
Figure 8. W-20-17-GFP+ and W-20-17-ACVR2A-V5+ cells were
serum-restricted for twenty-four hours and then treated with 250
ng/ml Follistatin for four hours to examine the potential effect of
ACVR2A overexpression on BMP pathway activation. Western blot
analyses were performed for BMP pathway activation level
(phosphorylated SMAD1/5/8 compared to total SMAD1) with
beta-actin acting as a control. These preliminary results indicate
that Follistatin treatment has no effect on cells transduced with
lentivirus overexpressing ACVR2A. We anticipate that these
results provide evidence that Activin-mediated repression of BMP
signaling occurs at the level of receptor competition.
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Activin inhibition	upstream	of	receptor	engagement
Figure 3. W-20-17 cells were serum-restricted for twenty-four hours then treated with 250 ng/ml Follistatin for four hours.
Western blots were then performed for BMP pathway activation level (phosphorylated SMAD1/5/8 compared to total
SMAD1), with beta-actin acting as a control. These results indicate that Follistatin treatment alleviates Activin-mediated
repression of BMP signaling. * indicates p<0.05; n=3 per group.
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Abstract
Osteoporosis is a disease characterized by low bone mineral density due to the rate of bone resorption
exceeding that of bone formation. Substantial evidence indicates the Bone Morphogenetic Protein (BMP)
pathway promotes bone formation through action of the effectors SMAD1/5/8 while the Activin pathway
negatively influences bone mass through action of the effectors SMAD2/3. Recent studies suggest that BMPs
and Activins regulate bone mass in a see-saw-like mechanism. Here, we seek to test this hypothesis in vitro via
signaling responsiveness assays using pathway-specific western blot analyses in the osteogenic murine bone
marrow stromal cell line W-20-17. We first confirmed that W-20-17 cells exhibit basal activation of SMAD1/5/8
and SMAD2/3 under serum-restricted conditions. Moreover, treatment with Follistatin, which sequesters
Activin ligands in the extracellular environment, leads to an increase in BMP pathway activation. To determine
the molecular mechanism allowing for this relationship, we treated W-20-17 cells with SB431542, which is an
intracellular inhibitor of Activin signaling that functions downstream of receptor engagement, and found no
effect on BMP pathway activation. In contrast, treatment of W-20-17 cells with BMP pathway inhibitor Noggin
had no effect on Activin pathway activation despite robust inhibition of BMP signaling. Collectively, our results
suggest Activin-mediated repression of BMP signaling in these cells is ligand-dependent but occurs upstream of
SMAD2/3 activation. Gene expression analyses indicate that W-20-17 cells express Activin A and its receptors
ALK4, ACVR2A, and ACVR2B. Given that ACVR2A and ACVR2B also have high affinity for BMP ligands, this raises
the possibility that Activin-mediated repression of BMP signaling may occur via competition for a shared pool
of receptors. Over-expression studies coupled with osteoblast activity assays are currently underway to
examine this hypothesis. Collectively, our work seeks to elucidate the mechanism(s) that regulate antagonism
of BMP and Activin signaling pathways in the osteoblast lineage to identify novel opportunities for treating low
bone mass in humans.
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Figure 2. W-20-17 murine bone marrow stromal cells were serum-restricted for twenty-four hours then treated
with 250 ng/ml Noggin for four hours. Western blots were then performed for BMP pathway activation level
(phosphorylated SMAD1/5/8 compared to total SMAD1), and Activin pathway activation level (phosphorylated
SMAD2/3 compared to total SMAD2) with beta-actin acting as a control. These results indicate that Noggin
treatment had no effect on Activin pathway activation despite robust inhibition of BMP signaling. n=3 per group.
Figure 1. The BMP and Activin signaling pathways are initiated by ligand engagement with hetero-complexes
of type 1 and type 2 receptors. In the BMP pathway, ALKs2, 3, and 6 are type 1 receptors, each of which
activate the downstream effectors SMADs1, 5, and 8 in response to activation by a type 2 receptor (such as
BMPR2). Similarly, Activin ligands induce the type 1 receptors ALK4 or ALK7 to activate SMADs2 and 3.
Notably, ACVR2A and ACVR2B may serve as type 2 receptors for either. We conceptualize the effects of these
pathways in the skeleton as a see-saw mechanism, with BMPs generally promoting bone mass accrual and
Activins generally promoting bone mass loss.
BMP & Activin Signaling Pathways
